CDEX Inc. Signs Agreement With HealthContrax LLC to Distribute the ValiMed(TM) Validation System, Gaining Access to National Group Purchasing Organizations

TUCSON, AZ--(Marketwire - January 07, 2011) - CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com), a leading developer of chemical detection products, using patented technologies, for use in healthcare and security markets, announced today the signing of a new distribution agreement with HealthContrax LLC, an Iowa-based national accounts sales agency. The agreement provides CDEX with access to Group Purchasing Organizations (GPOs) that contract for thousands of hospitals, labs and clinics across the country. In partnering with HealthContrax, CDEX will gain immediate market access for its ValiMed™ Validation System product line across the US.

HealthContrax helps healthcare manufacturers gain market access, serving as a National Account representative agency helping companies navigate multiple markets, including acute care, long term care and alternate site segments. They connect both large and small healthcare manufacturers to the various channels they serve, extending the marketing reach and distribution for their manufacturing partners. With increased market access and usage of the ValiMed™ product line, hospitals and laboratories across the country will be able to reduce medication errors for patient safety and pharmaceutical drug loss prevention. The ValiMed System helps prevent human inaccuracy by validating the drug compounds, preventing high-risk, high-alert medication errors, narcotic diversion, counterfeit medications and non-compliance of regulatory guidelines in healthcare facilities.

“The distribution partnership with HealthContrax grants access to national Group Purchasing Organizations that contract with thousands of hospitals domestically, directly extending the sales reach for our ValiMed Validation Systems,” stated Jeff Brumfield, CEO and Chairman of the Board of CDEX Inc. “We believe HealthContrax is a great distribution partner and brings immediate access to agencies across the U.S., which should accelerate interest in our systems.”

“We met with the CDEX team at the ASHP Midyear Conference and were very impressed with the ValiMed Validation Systems,” stated Marc Marchand, CEO of HealthContrax. “We believe the ValiMed has tremendous market potential as hospitals and other healthcare agencies focus on patient safety and drug loss prevention.”

About HealthContrax LLC
HealthContrax helps healthcare manufacturers gain market access. It is a National Account rep agency helping companies navigate multiple markets, including acute care, long term care and alternate site segments. HealthContrax connects both large and small healthcare manufacturers to the various channels they serve.

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit www.cdex-inc.com

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.